Sonnet BioTherapeutics
VerifiedSonnet biotherapeutics is working on developing new immune therapeutics.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
($717k) (Public information from Jun 2024)
Share price
$0.94 SONN
Princeton New Jersey (HQ)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (28 %) | (58 %) | (21 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (5163 %) | (8463 %) | (12636 %) | (10598 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (5166 %) | (8493 %) | (12742 %) | (6094 %) | - | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 3440 % | 6128 % | 7993 % | - | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
* | N/A | $3.4m | Post IPO Equity |
| Total Funding | 000k | ||
Related Content
Recent News about Sonnet BioTherapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.